Crescendo Biologics
Colette has over 11 years’ experience in the biopharmaceutical industry, with a strong focus on transgenic platforms and antibody discovery. She has been at Crescendo since 2012. Prior to joining Crescendo, Colette held a senior scientific role in Antibody Discovery and Protein Engineering at MedImmune.
Before her industrial career she was an academic research scientist, interested in epigenetic control of gene regulation (MRC Clinical Sciences Centre, London), VDJ recombination and B cell development (Babraham Institute, Cambridge) and X chromosome dosage compensation (Welcome Trust Sanger Institute, Cambridge).
Colette holds a BSc degree in Biology from Manchester University, an MSc in Molecular Genetics from Leicester University and a PhD in Developmental Biology from King’s College London.
This person is not in any offices
Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).